A r t i c l e s Large numbers of potentially pathogenic mutations have been identified through exome sequencing of NDD cohorts, but in most cases only a single occurrence of a de novo mutation in a particular gene has been discovered. Substantially larger numbers of cases and controls are required to demonstrate the statistical significance of individual genes. Leveraging samples and data from multiple comorbid conditions, in principle, can increase sensitivity in identifying risk genes. Phenotypic follow-up of cases broadly drawn from NDDs has previously allowed us to explore specific clinical phenotypes in a genotype-first manner 5 , as in the case of genes such as CHD8 (ref. 6 ), DYRK1A 7 , and ADNP 8 .
Here, using single-molecule molecular inversion probes (smMIPs) 9,10 , we sequenced the coding and splicing portions of 208 potential NDD risk genes in over 11,730 ASD, ID, and DD cases. smMIPs provide a highly sensitive, specific, and inexpensive approach to sequence the protein-coding portions of a moderate number of candidate genes in a large number of cases. Samples were collected as part of an international consortium termed the Autism Spectrum/ Intellectual Disability (ASID) network, involving 15 centers across seven countries and four continents. The collection has the advantage over many others in that subsequent phenotypic follow-up is possible for a large fraction of the cases.
RESULTS

Mutation discovery
We selected 208 candidate NDD (ASD, ID, and DD) disease-risk genes, on the basis of published sequencing studies [11] [12] [13] [14] [15] [16] [17] ( Supplementary  Tables 1-3) , by using denovo-db 18 . Genes were selected and ranked according to the number of published de novo recurrences, overlap with a CNV morbidity map 19 , pathway connectivity 20 , and absence of de novo variants in 1,909 published unaffected-sibling control exomes 12, 13 . We designed 12,016 smMIPs distributed across four smMIP pools to cover all annotated RefSeq coding exons as well as 5 bp of flanking intronic sequence ( Supplementary Tables 4-7 and Online Methods). We targeted these genes for sequencing in 15 large cohorts of cases (some including unaffected siblings) with a primary ascertainment diagnosis of ASD, ID, or DD, for which exome sequencing had not previously been performed (Supplementary Tables 8 and 9 ). The set included 6,342 cases with a primary diagnosis of ASD and 7,065 cases with a diagnosis of ID/DD, from a large international collaboration between research and clinical investigators from the United States, Belgium, the Netherlands, Sweden, Italy, China, and Australia ( Fig. 1) .
After quality control (QC) (Online Methods, Supplementary Table 10 and Supplementary Figs. 1-4) , we identified 61,315 QC-passing variants, excluding common dbSNP variants. Of these, 2,185 were private (i.e., found in only one family in the study; Supplementary Tables 10 and 11) and potentially deleterious (for example, nonsense, stop-gain, start-loss, frameshift, or disruptive splicing mutations) or missense events with a combined annotation-dependent depletion (CADD) score >30 (MIS30). The number of private, high-impact events identified in probands was significantly greater than that in unaffected siblings in the study (false discovery rate (FDR)-corrected P = 1.44 × 10 −9 ; two-tailed Fisher's exact test; Supplementary Fig. 5a,b) , as expected 9, 11 . This signal was primarily driven by likely gene-disruptive (LGD) events (corrected P = 9.20 × 10 −15 ) and not MIS30 events (corrected P = 0.83). We validated 1,125 variants, including all private LGD events as well as 25% of the private MIS30 events, by Sanger sequencing (validation rate >97%; Supplementary Table 11 ).
Genes with an excess of severe de novo mutations
We assessed inheritance for 286 of the private variants, 35% of which were determined to be sporadic mutations ( Supplementary Tables 12  and 13 , and Supplementary Fig. 5c ). The set represented 91 private de novo mutations- 82 LGD and 9 MIS30-among cases and 9 de novo mutations- 3 LGD and 6 MIS30-among unaffected siblings, and included 35 recently reported events 11, 12, 21 ( Supplementary Table 12 and Supplementary Fig. 5d ). Allowing for an allele count (AC) ≤3, we identified an additional 32 de novo LGD and 15 de novo MIS30 events in probands, for a total of 138 de novo proband events (114 LGD and 24 MIS30 ; Supplementary Table 12 ). Using a probabilistic model derived from human-chimpanzee divergence and an expected rate of 1.5 de novo mutations per exome 9, 22 , we calculated the overall probability of detecting 114 or more de novo LGD and 24 de novo MIS30 variants in our panel of 208 genes as P = 1.6 × 10 −22 (one-tailed binomial test) with an odds ratio (OR) of 2.62 (95% confidence interval (CI) 2.2-3.09). By combining these results ( Supplementary Table 12 ) with published exome data sets ( Supplementary Tables 1 and 2) , 13 A r t i c l e s A r t i c l e s we identified a total of 393 de novo LGD and 98 de novo MIS30 events in 208 screened genes, thus increasing the significance (P = 1.28 × 10 −218 ; OR = 6.46 (95% CI 5.89-7.06)). Excluding known high-risk NDD genes ( Supplementary Table 3 ), we recalculated the probability of identifying 136 or more de novo LGD and 13 de novo MIS30 variants among the 84 unknown genes ( Supplementary Table 3 ) in which at least one de novo LGD mutation has been identified. The frequency of de novo mutations was significantly increased in probands (P = 1.32 × 10 −55 , OR = 5.12 (95% CI 4.33-6.01)), thus suggesting that many of these remaining genes contribute to NDD pathology. Combining both smMIPs and exome sequence data, we identified 68 genes that reached de novo significance for LGD mutations and 23 genes that reached de novo significance for MIS30 mutations, at the level of the individual gene (q <0.1 by binomial test and more than one LGD or MIS30 event in probands; Table 1 , Fig. 2a -c, Supplementary  Fig. 6 , and Supplementary Table 14 ). Thirteen genes were significant for both de novo LGD and MIS30 genes; thus, 78 unique genes showed an excess of de novo mutations in cases ( Table 1) . Ten (13%) of these genes were unique to the MIS30 category for probands: TANC2, TRIO, COL4A3BP, TBL1XR1, PPP2R5D, DLGAP1, SRGAP3, PTPN11, ADCY5, and ITPR1 ( Table 1 and Supplementary Table 15 ). Thirty-nine of the de novo LGD and seven of the de novo MIS30 significant genes have been previously linked to NDDs in the literature ( Table 1 and Supplementary Table 15 ). Of the 78 de novo significant genes, 32 have not been previously described as being associated with NDD phenotypes. The most significant of these genes were TRIP12, KMT5B, and ASH1L ( Fig. 3) , which were significant for both de novo LGD and MIS30 mutations, and NAA15 and DSCAM 11 , which were significant for only de novo LGD mutations (corrected P < 1 × 10 −6 ). The most frequently de novo-mutated genes in this study were SCN2A, ADNP, CHD8, DYRK1A, and POGZ ( Supplementary Table 13 ). De novo mutations in NAA15 were also seen as frequently as those in DYRK1A and POGZ ( Supplementary Table 13 ). No genes reached de novo LGD significance in unaffected-sibling controls, although one gene, TRRAP, reached de novo MIS30 significance among the controls. Although it is possible that de novo mutation of this gene is protective, it is more likely that TRRAP represents a false positive, possibly because of a mutation rate higher than expected from our statistical model.
Inherited mutations and burden
The majority of validated LGD and MIS30 private variants were inherited (65%) from either mothers (33.2%) or fathers (31.8%) ( Supplementary Table 13 and Supplementary Fig. 5e ). Among these variants, together with additional ultrarare (AC ≤3) inherited events ( Supplementary Table 16 ) and published private inherited counts from exome sequencing of the Simons Simplex Collection (SSC) 13 ( Supplementary Table 17 ), we observed a nominally significant maternal transmission bias for LGD (but not MIS30) events (P = 0.037, binomial test, with sex-chromosome events excluded). Although this analysis was underpowered to detect specific genes at the single-gene level, several genes showed an increased number of maternal transmissions (≥3:1 ratio; i.e., AHNAK, DSCAM, NRXN1, NISCH, UIMC1, PLXNB1, PROX2, CHD1, TNRC18, PTK7, and MOV10; Supplementary Fig. 7) .
We also estimated the burden of private LGD and MIS30 variants at the single-gene level, regardless of inheritance status, by comparison with controls from the Exome Aggregation Consortium (ExAC) database, in which neuropsychiatric cases had been excluded (n = 45,376; Supplementary Table 18 ). Separate simulations of LGD and MIS30 events identified 30 and 13 genes with a significant LGD burden and MIS30 burden, respectively (1 × 10 6 simulations with Benjamini-Hochberg correction; Table 2 and Fig. 2d,e ). Four genes (FOXP1, GRIN2B, SCN2A, and SETD5) were significant for both LGD and MIS30 burden and are well-established NDD genes. Interestingly, 18 genes (eight LGD and ten MIS30) had a significant burden of private disruptive mutations in this study but did not reach de novo significance, probably because of our inability to test inheritance for A r t i c l e s all events. Although de novo mutations in some of these genes have already been implicated in other NDD studies (for example, FOXP1, TRIO, SCN1A, SIN3A, and IQSEC2) [23] [24] [25] [26] [27] , for others (CTNND2, NAV2, and UNC80), many of the severe mutations in pedigrees are inherited ( Supplementary Tables 11 and 16 ). Given their involvement in neuronal function, axonal projection, dendrite spine formation and oligodendrocyte differentiation [28] [29] [30] [31] , these genes probably begin to define a class of inherited high-impact risk factors.
Autism versus intellectual disability and developmental delay
To determine whether individual genes showed a bias for clinical phenotype, we performed a separate burden analysis by using primary ascertainment diagnoses (i.e., ASD or ID (including DD diagnoses, per DSM-5 criteria)) combined with data from previous NDD studies 13 ( Supplementary Tables 2, 11 , and 17). We identified 25 genes showing a bias for primary diagnosis (two one-tailed binomial tests, P <0.025 for either ASD or ID/DD cases), considering both LGD and MIS30 ( Fig. 4a) . Eight genes had an ASD bias (CHD2, CTTNBP2, CHD8, LAMC3, DIP2A, RELN, UNC80, and IQGAP3). Of these, only CHD8, CHD2, and DIP2A have previously been implicated as high-risk ASD loci 32 . Of the 17 ID/DD-biased genes, NAA15, ZMYM2, PHIP, and STAG1 have not previously been linked to these phenotypes. We further separated the LGD and MIS30 events and identified additional significant genes for each mutation type, notably a bias for CDH10
LGD and NEMF MIS30 mutations in ASD ( Supplementary  Fig. 8a ) and SCN1A LGD and NRXN1 MIS30 mutations in ID/DD ( Supplementary Fig. 8b ). Most genes, however, were mutated in both conditions, thus further highlighting the substantial genetic overlap between these comorbid conditions.
Phenotypic assessment of new risk genes
We recontacted individuals with mutations in NAA15, KMT5B, and ASH1L for further follow-up. We identified 12 LGD variants and one MIS30 private variant ( Supplementary Table 11 ) in NAA15 through our smMIP screening ( Fig. 3a) and determined that four LGD mutations were sporadic, whereas two LGD variants, including a C-terminal mutation, were inherited ( Supplementary Table 11 ). NAA15 shows a burden of LGD events in cases ( Table 2) as well as an excess of de novo LGD variants ( Table 1 ). The gene NAA15 encodes a protein that is a component of the NatA N-acetyltransferase complex, which includes NAA10-a d e 30 20 LGD odds ratio LGD
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Observed (-log 10 (P)) PPP2R5D  ZC3H4  SETD2  UNC80  WDFY3,PLXNB1  LAMC3  IQSEC2  ZMYND11  ZBTB45  DOCK8  SPP2,PHF7  GRIA2,MFRP  UBN2,TUBA1A  RALGAPB  ERBIN  MOV10  CSTF2T  CTTNBP2,NCOR1  VCP  TANC2  SHANK2   SRCAP,SYNCRIP  ARIH1  TBL1XR1  PHF2  DIP2A  ZNF292, Figure 2 Targeted sequencing highlights genes reaching significance for de novo mutations and private disruptive variant burden. (a-c) Quantile-quantile plots comparing the probability (FDR corrected, inverse log transformed) of recurrent de novo mutation for individual genes among proband samples compared with a uniform distribution, given the number of genes tested (dashed gray line, significance threshold). Gray dashed boxes in a and b are shown in zoom view in b and c, respectively. Asterisk, genes that reached significance for mutation burden. (d,e) Scatter plots depicting the OR for private variants compared with unaffected controls from ExAC (y axis) versus the FDR-corrected de novo P value (one-tailed binomial test) (x axis; values are inverse log transformed for plotting) according to gene. Gray lines, significance threshold for the de novo P value (horizontal) and an OR of 2 (vertical). Genes are classified as de novo significant and OR >2 (red dots), OR >2 only (orange), and showing a significant de novo P value only (blue). Gene-name labels indicate a significant burden (FDR q <0.1, simulation test) of either private LGD (d) or MIS30 (e) mutations in probands ( A r t i c l e s protein that is associated with Ogden syndrome as well as nonsyndromic DD 33 and is thought to tether the complex to the ribosome for posttranslational modification of proteins as they exit the ribosome 34 . To identify additional patients for clinical recontact, we relaxed our variant filter to allow for ultrarare (AC ≤3) alleles. In total, we collected clinical information for ten probands with private variants and three probands with ultrarare variants in NAA15 ( Supplementary Table 19 ). Cases in our study with NAA15 LGD and MIS30 mutations shared phenotypic features, including ID (10/11 cases; 91%), speech delay (5/6 cases; 83%), ASD diagnosis (formal diagnosis in 5/8 cases (63%) with ASD-like traits observed in two additional cases), and nonspecific growth abnormalities (for example, microcephaly, macrocephaly, and hypertelorism) ( Supplementary Table 19 ). Given the incidence of DD (5.12%) in the general population 35, 36 , we estimated the penetrance of LGD NAA15 mutations to be substantial at 35.3% (95% CI 15.7-63.6%). Both KMT5B and ASH1L encode histone lysine N-methyltransferase proteins thought to be important in chromatin modification, occupancy and gene regulation. Although the roles of these genes in NDDs have not been established, a paralog of ASH1L, SETBP1, has been reported to be mutated in NDD and to be associated with ID and loss of expressive language 19 . We identified two de novo LGD mutations and two de novo MIS30 mutations in KMT5B in this study ( Supplementary Table 12 ) in addition to three published de novo LGD variants and one de novo MIS30 variant 12, 14 (Fig. 3b and Supplementary Table 2 ). We were able to collect clinical information from three probands with private variants and four probands with ultrarare variants in KMT5B ( Supplementary Table 20 ). Individuals with disruptive variation in KMT5B shared features such as ID/DD (7/7 cases; 100%), ASD diagnosis (5/6 cases; 83%), language delay (3/4 cases; 75%), motor delay (3/5 cases; 60%), and febrile seizures (3/5 cases; 60%). Attention deficits were also observed in three of these patients ( Supplementary Table 20 ). For ASH1L, we identified two de novo LGD mutations and two de novo MIS30 mutations in addition to the three previously published de novo LGD mutations 13, 14 . We identified many additional LGD and MIS30 variants in ASH1L for which parental DNA was not available ( Fig. 3c ) and found that mutations clustered around the known annotated protein domains. We were able to obtain clinical information for two probands carrying private variants and three probands carrying ultrarare ASH1L variants. Individuals with ASH1L disruptive variation in this study had ID (5/5 cases; 100%), ASD (2/3 cases; 67%), and evidence of seizures (2/3 cases; 67%) ( Supplementary Table 21 ).
Phenotypic comparisons and a high-functioning ASD network
We selected patients with de novo LGD mutations in 25 of our topranked genes in an effort to more broadly compare phenotypic features. Of the recontacted individuals, 70% (88/125) agreed to participate in a more comprehensive phenotypic evaluation. To increase our power to detect differences among patients, grouped by gene, we combined 215 case reports from the published literature with the findings collected as part of our recontact study. We assessed the general severity of each NDD by using a modified de Vries scale ( Supplementary Table 22 ) and summarized phenotypic features collected during follow-up ( Table 3) , including rates of ASD, ID, seizures, macro-and microcephaly, and congenital abnormalities as well as mean IQ measures and ASD severity.
Several specific and global patterns emerged from this combined data set, in particular, an inverse relationship between ASD and ID A r t i c l e s diagnoses by gene (Pearson's R = -0.81, P = 9.84 × 10 −7 ; Fig. 4b ). We partitioned cases into two categories: those most strongly associated with ASD (diagnostic rate >95%) and those more strongly associated with DD. Individuals with mutations in ASD genes showed significantly lower rates of seizures (P = 1.20 × 10 −4 ), congenital abnormalities (P = 1.88 × 10 −2 ), and microcephaly (P = 1.79 × 10 −7 ), but higher rates of macrocephaly (P = 5.25 × 10 −3 ), as compared with comorbid ASD and ID genes and strong ID genes (two-tailed Fisher's exact test; Fig. 4c ). In addition, the ASD-dominated genes showed a significant difference with respect to sex. ASD genes were more likely (P = 1.65 × 10 −4 ) to affect males, showing an overall ratio of 4:1 when compared with other genes (1.2:1 male/female ratio). Although the number of individual patients per gene was still low, interestingly, several genes showed an exclusive male bias (KDM6B, DSCAM, WDFY3, CHD1, and WDR33; Fig. 4c and Table 3 ). Pathway analysis of the 11 ASD genes indicated a functional enrichment in chromatin remodeling (corrected P = 4.72 × 10 −3 ; Enrichr tool) 37 , thus implicating a functional network specifically associated with ASD individuals without ID.
To identify additional genes that may be specifically associated with high-functioning ASD, we revisited the deep phenotyping data collected as part of the SSC and applied the MAGI network-building tool, which compares the spectrum of de novo mutations in probands and unaffected siblings to identify coexpression and protein-interaction networks enriched in patients 12, 13, 20 . We specifically selected patients with a full-scale IQ (FSIQ) >100 (n = 668 SSC probands; male bias 9:1) to construct a protein-interaction network based on genes with de novo variants in this subset (Online Methods). One statistically significant model emerged (P < 0.01, simulation test; Fig. 4d ), including 40 genes and de novo mutations in 31 individuals with FSIQ >100. Although it was primarily composed of de novo missense mutations, the network showed that de novo LGD mutations in FBXW11, CHD1, CHD8, DOT1L, HDAC3, YTHDC1, and KLHDC10 may be Benjamini-Hochberg corrected for the number of genes screened in which at least one private mutation was found in cases or controls (n = 176). Genes significant for LGD burden are shown first, followed by MIS30-burden-significant genes, from most to least significant. Genes in this table are labeled in Figure 2d ,e. Corrected P values <0.1 were considered significant.
A r t i c l e s important in this patient subset. Both CHD1 and CHD8 individuals were included in our large-scale patient recontact and showed high specificity for ASD diagnosis ( Table 3) . A pathway analysis for this specific set of genes again implicated chromatin remodeling (P = 0.0003, Benjamini-Hochberg corrected Fisher's exact test (twotailed)) as well as mRNA splicing (P = 0.00026) and Wnt signaling (P = 0.03) as potentially being important in ASD without ID.
Functional characterization of candidate genes in Drosophila
To provide additional functional evidence, especially with respect to nervous-system function and behavior, we performed a pilot study investigating 21 genes in Drosophila melanogaster ( Supplementary  Table 23 ). For 11 of these genes, de novo LGD mutations were significantly enriched in NDD patients. For the other ten genes, there were indications of possible association with ASD, such as a higher mutation rate in ASD cohorts or a central position in ASD gene interaction networks 20 . Others, such as NCKAP1 and WDFY3, were at the cusp of statistical significance. We used the UAS-Gal4 system and inducible RNA interference (RNAi) lines to specifically knock down these genes in Drosophila neurons. When their locomotor function and overall vigor allowed ( Supplementary Table 23 ), we subjected these knockdown flies to an ASD-and ID-relevant behavioral assay measuring light-off jump habituation, which has been shown to be affected in a number of ASD-or ID-related Drosophila models [38] [39] [40] [41] [42] [43] .
In this assay, flies suppress their startle (jump) response to a repeated nonthreatening stimulus (light-off) as a result of experience. Their response thus gradually wanes (Fig. 5a,b) . As the most fundamental evolutionarily conserved form of learning, habituation is thought to represent a prerequisite for higher cognitive functions 44 . Beyond that, a number of studies have shown defective habituation of neural activity or behavior in ASD [45] [46] [47] [48] , and it has been proposed that disturbed habituation mechanisms may substantially contribute to defective filtering and other ASD features 49, 50 . We first examined genes for which a significant excess of de novo LGD mutations (NAA15, KMT5B, ASH1L, and TCF4) was observed, and for which human phenotypic data strongly support a role in (d) SSC probands with ASD and an FSIQ >100 were selected for pathway enrichment. Node size indicates the mutation score (calculated by MAGI on the basis of the number of de novo mutations), and the color of the node indicates the number of de novo LGD (red) and de novo missense (no CADD cutoff; blue) mutations observed in affected probands. For SPEN, two LGD and one missense mutation were observed, and for RANBP2, one LGD and one missense mutation were observed. White nodes indicate no de novo mutations observed. Gray lines connect genes with both protein-protein interactions and brain coexpression (Pearson's correlation coefficient r 2 > 0.37; Online Methods). Thicker lines correspond to more highly coexpressed gene pairs.
A r t i c l e s NDDs. After knockdown of Nat1 (ortholog of NAA15, Vienna Drosophila RNAi Center (VDRC) no. 110689), we observed erect wings, impaired locomotor activity, and adult early lethality (within 1 or 2 d after eclosion). After knockdown of Nat1 in a second presumably weaker RNAi line (VDRC no. 17571), flies exhibited normal morphology and locomotion; however, when challenged in the light-off jump paradigm, the flies' initial response was impaired (19% frequency of initial jumping), thus precluding proper assessment of habituation ( Supplementary  Table 23 ). These results supported Nat1's crucial role in nervous-system development.
Ash1 (ortholog of ASH1L) neuronal-knockdown flies also showed decreased fitness, and, like Nat1 flies, could not be scored in the habituation paradigm. Hmt4-20 (ortholog of KMT5B) and da (ortholog of TCF4) flies, in contrast, were healthy overall but showed specific and significant habituation deficits (Fig. 5a,c) , thus suggesting that both genes play important roles in the molecular machinery that regulates habituation learning. We observed habituation defects after knockdown of fly homologs for several other significant de novo-mutated genes, including SYNGAP1, GRIN2B, and SRCAP ( Fig. 5c and Supplementary Table 23 ). In addition, dom (SRCAP) and da (TCF4) flies showed substantial morphological abnormalities at the neuromuscular junction (NMJ), a well-studied synaptic model system (Supplementary Fig. 9 ). NCKAP1, WDFY3, and GIGYF2 were among the tested genes with borderline significance, on the basis of our human genetic data. Significant habituation defects were observed for flies with hem (ortholog of NCKAP1), bchs (ortholog of WDFY3), and Gyf (ortholog of GIGYF2) knocked down ( Fig. 5c and Supplementary  Table 23 ). Owing to the paucity of cases, little is known regarding the clinical phenotypes associated with loss-of-function mutations of these genes; however, these functional studies suggest that they have an important role in neuronal and cognitive function.
DISCUSSION
Targeted sequencing of candidate genes in a large NDD cohort identified three overlapping categories of high-risk genes. First, we identified 68 genes that reached de novo LGD mutation significance, 39 of which have previously been described. Owing to limited availability of parental samples, this estimate is probably conservative. Second, we highlighted 24 genes with a significant excess of de novo missense mutations in NDD patients; 63% (15/24) overlap genes with de novo LGD Mean ASD severity was derived from the ADOS-2
Calibrated Severity Score (CSS) and ranged from 1 to 10; scores between 4 and 10 represent symptoms of ASD, with 10 being the most severe.
A r t i c l e s significance (for example, SCN2A, STXBP1, CHD2, and CASK), whereas others were significant only on the basis of an excess of de novo MIS30 mutations (for example, COL4A3BP, TRIO, TBL1XR1, and PPP2R5D; Table 1 ), similarly to the Noonan-syndrome gene (PTPN11) 51 . Finally, 39 genes reached statistical significance on the basis of case-control burden testing ( Table 2) . Of interest were the 13 genes without de novo-mutation significance (SMARCC2, CTNND2, SIN3A, SCN1A, NFIA, CDKL5, DNAJC6, IQSEC2, IQGAP3, ADGRL2, ERBIN, NAV2, and AGAP2; Table 2 ), which may be potential inherited risk factors 13, 31, 52 . In total, 44% (91/208) of our candidate genes reached locus-specific significance for disruptive mutations in 5.7% of patients, a result closely matching empirical expectations 12 . However, mutation of these genes may not be necessary and sufficient to result in disease; for example, nine families ( Supplementary Fig. 10 ) had disruptive mutations in two or more of the candidate genes.
Three genes without previous phenotypic information reached a high level of de novo significance (NAA15, KMT5B, and ASH1L). NAA15 was originally identified as an N-methyl-d-aspartate (NMDA) glutamate-receptor-regulated gene through screens of Nmdar1knockout mice 53 . Knockdown of Naa15 in Drosophila neurons caused severe locomotor defects and lethality. Missense mutations in the NAA15-interacting gene NAA10 are known to cause Ogden syndrome, an X-linked disorder of infancy that can result in severe DD, craniofacial anomalies, hypotonia, cardiac arrhythmias, and, in some cases, death 54 . This finding is consistent with the DD observed in our cases and the identification of de novo LGD mutations in people with congenital heart disease and NDDs 55 . The identification of KMT5B and ASH1L highlighted the importance of histone methyltransferases, such as EHMT 56 , in ID and NDD. Mouse studies have shown that, in neurons, Ash1l protein represses Nrxn1α protein, a known presynaptic adhesion molecule required for synaptic formation 57 ; mutations in NRXN1 have been associated with ASD 58 . Even less is known about the role of the KMT5B protein in the developing brain. However, studies have suggested that the histone H4 K20 trimethyl mark established by the KMT5B protein may be involved in cellcycle regulation in baboon neural stem progenitor cells 59 . Our own analyses in Drosophila support roles of NAA15 and ASH1L in neuronal development and of KMT5B and TCF4 in habituation learning ( Supplementary Table 23 ), in agreement with patient phenotypes (Supplementary Tables 19-21) .
We designed the study such that approximately half of the cases were ascertained on the basis of a primary diagnosis of ASD, whereas the other half were diagnosed initially as ID/DD in an effort to test the diagnostic specificity of particular genes. Although most genes are clearly risk factors for NDD in a broad sense 4 , secondary analyses of both the genetic burden and subsequent patient follow-up for 25 genes in 303 cases did highlight genes with a statistical bias toward ASD versus ID/DD diagnosis (Table 3 and Fig. 4c ). We found that individuals with mutations in genes enriched in ASD showed significantly lower rates of seizures, congenital abnormalities, and microcephaly, but higher rates of macrocephaly compared with those for comorbid ASD and ID genes and strong ID genes (Fig. 4c) . The latter finding is interesting in light of the observation of increased brain sizes and/or weights at early ages in subtypes of ASD, as compared with those associated with ID or found in typical toddlers [60] [61] [62] [63] . Although the number of exome-sequenced cases with a de novo mutation was small (4.6% or 31/668 patients), the data highlight a coexpression and protein-interaction network statistically enriched in high-functioning autism patients (FSIQ >100) compared with unaffected siblings. This network is biased for de novo missense compared with LGD mutations (2:1), thus indicating that less severe mutations may play a role in ASD without ID. The network highlights mRNA splicing as well as genes important in chromatin remodeling. The latter implicate early developmental programs that regulate cell proliferation, neural patterning and differentiation, axonal guidance consistent with cellular ASD models [64] [65] [66] , and ASD postmortem 63, 67, 68 , genomic 69, 70 , and developmental imaging [60] [61] [62] 
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
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ONLINE METhODS
Patient samples. Whole-blood or cell-line DNA from patients with ASD, ID, or DD diagnoses were collected from 15 international clinical and research cohorts ( Fig. 1) . Only DNA samples from The Autism Simplex Collection (TASC) and Autism Genetic Resource Exchange (AGRE) cohorts were derived from cell lines. Clinical workup, including diagnostic evaluation, medical examination, and neuropsychological assessment was made available for many patients upon request, specifically for patients with mutations in NAA15, KMT5B, and ASH1L (case reports in Supplementary Note). Best-estimate clinical DSM-5 diagnoses were made by experienced, licensed clinicians on the basis of all available information collected during the evaluation. Descriptions, the number of individuals represented, and the primary ascertainment criteria for each cohort in this study are shown in Supplementary Table 8 . In addition, 2,867 unaffected-sibling control individuals were analyzed for genetic and phenotypic comparison (Supplementary Table 9 ). All experiments carried out on these individuals were in accordance with the ethical standards of the responsible institutional and national committees on human experimentation (the University of Washington Institutional Review Board approved the human research performed in this study), and proper informed consent was obtained for sequencing, recontact for inheritance testing, and phenotypic workup. All sequencing of patient samples was performed at the University of Washington.
Detailed descriptions of clinical cohorts. Autism Clinical and Genetic
Resources in China (ACGC). This cohort has been described previously 21 .
Autism Genetic Resource Exchange (AGRE). This cohort has been described previously 71 .
Leuven. The Leuven cohort consists of patients with ASD, as diagnosed by the multidisciplinary team in the Expert Centre for Autism Leuven according to DSM-IV-TR (American Psychiatric Association, 2000) criteria. All patients were examined by a clinical geneticist. Patients with known monogenic conditions were excluded after a routine genetics workup.
Melbourne & Murdoch. All participants had a DSM-IV or DSM-5 diagnosis of ASD. Diagnoses were community based and were performed by a multidisciplinary team (pediatrician, psychologist, and speech pathologist). Diagnoses were confirmed for research purposes through ascertainment of previous ASD and cognitive assessments and a telephone interview with the parents. Information about pregnancy and birth, developmental milestones, comorbidities, medications, and general health was collected during the interviews and from medical records. Current ASD symptomatology was measured via the Social Responsiveness Scale (SRS) or Social Responsiveness Scale, 2nd edition (SRS-2). For each family, pedigrees were constructed detailing the family's history of medical conditions, mental health disorders, intellectual impairment, ASD diagnoses and ASD traits. DNA was collected from blood or saliva from probands and their parents. Most probands underwent molecular karyotyping for CNVs and single-nucleotide polymorphisms and fragile-X DNA testing; older participants had routine karyotyping.
The Autism Simplex Collection (TASC). This cohort has been described previously 72 .
Adelaide. Individuals with intellectual disability or developmental delay were recruited who were referred but were negative in molecular testing for fragile X and exhibited large CNVs in array comparative genomic hybridization (CGH). The majority were also singletons and were recently clinically diagnosed/ascertained patients, for recontacting purposes.
Leiden. The cohort consists of patients with developmental delay with or without autistic features. Clinical microarrays to detect CNVs were run on all index patients, and identification of a likely causal CNV was an exclusion criterion. No formal DSM criteria were used in the diagnoses. All patients were seen by experienced clinical geneticists and, if indicated, specific gene tests were requested. Parents of the patients provided verbal consent for inclusion in this study.
Stockholm. For all cases, array CGH was performed on an Agilent platform with a 180K genome-wide design. The cases were referred for genetic investigation after receiving a diagnosis of ID/ASD, but the DSM-5 guidelines were not used systematically.
Candidate-gene selection. Candidate genes with de novo mutations were identified from whole-exome and targeted-sequencing studies of ASD, ID, and DD, on the basis of previously published studies, and included 4,874 probands with ASD 9,11-14 , 151 probands with ID 15, 16 , and 1,133 probands with DD 17 (Supplementary Table 1) . Genes were ranked on the basis of the following criteria: (i) presence of two or more LGD mutations; (ii) presence of multiple missense mutations and at least one LGD mutation; (iii) presence of at least one LGD mutation overlapping a region of interest in our published DD CNV morbidity map 19 ; and (iv) presence of at least one LGD mutation with network connectivity to either chromatin remodeling/transcription or long-term potentiation, as described previously 20 . Genes with expression in the brain (on the basis of the BrainSpan Atlas of the Developing Human Brain) and GTEx databases 73 ) were prioritized. We eliminated genes associated with likely unrelated disorders in OMIM, and genes that were deemed highly mutable (on the basis of data from 6,503 control individuals in the NHLBI GO Exome Sequencing Project). Finally, we filtered genes according to the number of de novo mutations by whole-exome sequencing among unaffected siblings from the SSC [11] [12] [13] . More details on selection criteria can be found in Supplementary Table 3 . smMIP sequencing and variant validation. smMIP sequencing was performed as previously described 9, 10 . We targeted the coding portions of all RefSeq annotated transcripts for these 208 genes as well as 5 bp into each exonadjacent intron to capture variation at splice-donor/acceptor sites, thus resulting in the design of 12,016 smMIPs. smMIPs were split into four pools (Gold, ASD4, ASD5, and ASD6; gene breakdown in Supplementary Tables 4-7) , and each pool was rebalanced so that poorer-performing smMIPs were spiked in at a concentration of 10× or 50×. Approximately 192 samples per lane were barcoded and sequenced with an Illumina HiSeq 2000, as previously described 11 , and data analysis was performed with the MIPgen suite of tools. Variant calling of smMIP data was performed on each sequencing lane with FreeBayes v0.9.14 with default settings and the hg19 reference. For each of the four pools, all FreeBayes output was combined with GATK. Allele counts per genotype (AC) and the total number of alleles per genotype (AN) were recalibrated on the combined variant set with VCFtools. Multiallelic sites were split into separate entries with vcflib (vcfbreakmulti), and we removed sequencing-error repeats and common single-nucleotide polymorphisms (all of dbSNP v129 and variants found in dbSNP v141 at a minor-allele frequency ≥0.01 in at least one major population with at least two unrelated individuals having the minor allele). From the individual genotypes with sequencing depth (DP) of >8× and a quality score (QUAL) of >20, a private filter (found in only one family in the study) was applied to each pooled data set (i.e., ASD4, ASD5, ASD6, or Gold). These variants were annotated with the Ensembl Variant Effect Predictor tool for GRCh37 and with CADD scores 74 . All private LGD variants and a portion of MIS30 variants were validated by Sanger sequencing. Specifically, a CADD >30 was chosen for validation, because these events are very rare (<0.1% of all missense events in control genomes 75 ) and are more likely to be pathogenic 21 . When available, parents were also Sanger sequenced to determine the inheritance status of these variants. In total, we targeted >16,000 unique samples, including 13,407 probands and 2,867 unaffected siblings, by using each of the four smMIP pools. 1,744 of the DNA samples did not have sufficient DNA for all four pools; gene sets were prioritized on the basis of potential disease significance (Gold > ASD4 > ASD5 > ASD6; Supplementary Table 10) , with 13,407 probands (Gold), 12,192 probands (ASD4 and ASD5), and 11,731 probands (ASD6). In addition, we sequenced 2,867 unaffectedsibling samples with each of the four pools. To determine the performance of each smMIP pool, ten plates of unaffected siblings (960 samples) were compared in each pool by plotting the frequency of these 960 samples that reached at least 8× sequencing coverage for each individual smMIP in the study ( Supplementary Table 3 ). Each of these data points was plotted by gene within each pool (i.e., Gold, ASD4, ASD5, and ASD6, shown in Supplementary Figs. 1-4, respectively) . 165 genes passed all QC metrics (75% of smMIPs by gene reached at least 8× coverage in ≥80% of controls), but some exons, owing to their size or GC composition, did not pass these thresholds. For those regions that did not pass QC, we considered variant genotypes identified in samples if they were of high quality (read depth (DP) >8, phred scaled QUAL >20); however, these variants were not considered for assessments of mutation burden.
Clinical recontact and phenotyping. To systematically compare the effects of particular LGD mutations of targeted genes on phenotype, we recontacted individuals with identified LGD mutations and conducted a comprehensive phenotypic workup assessing function across multiple domains. No statistical method was used to predetermine sample size. The experiments were not randomized and were not performed with blinding. Per our human-subject approval, we recontacted only individuals who had consented to be approached about future studies during their original assessment. Families were invited to participate in a comprehensive clinical workup that included diagnostic evaluation, medical examination, and neuropsychological assessment (test battery and procedures in Supplementary Note). Importantly, all assessments were conducted by examiners naive to the individual's genetic event, thereby decreasing clinician bias in rendering diagnostic dispositions. To make comparisons across groups with similar LGD mutations, each participant was scored according to a modified version of the de Vries scale as a proxy for the overall severity of the phenotype [76] [77] [78] . The modified de Vries scale included the presence of facial dysmorphisms, congenital abnormalities, postnatal head growth abnormalities, ID/DD, and the number of DSM-5 diagnoses and medical diagnoses conferred, thus yielding a score ranging from 0 to 12 ( Supplementary Table 22 ). Data collected from these patients were combined with published case reports to increase our power to detect enrichments among patients sharing de novo LGD mutations in the same gene or pathway. A total of 323 case reports of individuals with de novo LGD mutations of interest and relevant data were included. The relevant phenotype data extracted from cases in the published literature were combined with information collected from individuals that were able to complete the in-person comprehensive evaluation. The modified de Vries scale scores for individuals with the same disrupted gene were averaged and then rank-ordered to estimate the effect of the gene mutation on phenotype. Only genes with six or more study participants and published case reports were included in the analysis. Patients that were considered had LGD mutations in one of the following genes: ADNP, ARID1B, CHD2, CHD8, CTNNB1, DYRK1A, FOXP1, GRIN2B, MED13L, POGZ, PTEN, SCN2A, SETBP1, STXBP1, or TBL1XR1.
Patient workups.
Comprehensive clinical workups included diagnostic evaluation, medical examination, and neuropsychological assessment. Best-estimate clinical DSM-5 diagnoses were made by experienced, licensed clinicians using all available information collected during the research evaluations. The battery included autism-specific diagnostic measures, the Autism Diagnostic Observation Schedule 79 and the Autism Diagnostic Interview-Revised 80 , both administered by research-reliable clinicians. The battery also included assessment of cognitive ability (Differential Ability Scales, DAS 81 ), language ability (Peabody Picture Vocabulary Test, 4th edition (PPVT) and Expressive Vocabulary Test, 2nd edition (EVT)), adaptive functioning (Vineland Adaptive Behavior Scales, 2nd edition),motor ability (Movement ABC; Purdue Pegboard), and behavioral and psychiatric disorders (Child and Adolescent Symptom Inventory, 5th edition (CASI-5), Child Behavior Checklist (CBCL), and Aberrant Behavior Checklist (ABC)). Medical diagnoses were assessed with the SSC medical history interview 82 and by physical examination by a developmental pediatrician conducting a standardized medical examination.
Participants undergoing comprehensive phenotypic assessment and published case reports in the literature were scored with an adapted de Vries scale as a proxy for the overall severity of the phenotype. Modifications included the removal of stature and prenatal-onset growth retardation, the inclusion of medical and psychiatric diagnoses, revision of weighting of intellectual disability into three points, and an increase to a total score of 12. Borderline intellectual disability or general delays were rated with one point, mild to moderate intellectual disability was scored with two points, and severe-profound intellectual disability was scored with three points. Psychiatric and medical diagnoses were tallied and scored as one if an individual had one diagnosis in these domains and was scored as two if the child had two or more diagnoses in these domains.
DSM-5 diagnoses included: ASD (299.00), attention-deficit/hyperactivity disorders (314.01, 314.00), language disorder (315. 39 Network analysis. We investigated modules significantly disrupted in highfunctioning-autism samples (full-scale IQ >100). We applied MAGI 20 on all of the samples from the ASD probands in SSC with FSIQ above 100. This subset of samples covered over 500 total de novo missense mutations and 100 LGD mutations. We applied the MAGI tool for module discovery on these variants by protein-interaction networks, gene coexpression networks and severe mutations reported in a control population from ESP (n = 6,500 individuals). The protein-interaction network used was a combination of networks from HPRD 112 and STRING 113 databases, and the coexpression network was built with the BrainSpan Atlas resource. The exact same training networks were used in our previous analysis for autism-module discovery 20 . The parameters were that the pairwise gene coexpression inside modules be, on average, at least 0.415 and the average protein-interaction density be 0.085. MAGI found one module of 40 genes significantly enriched in de novo mutations (P <0.01 on the basis of 100 random-mutation permutation tests).
Drosophila knockdown models. Drosophila orthologs of the genes of interest were determined with Ensembl, Unigene, and FlyBase databases 114, 115 . Their expression was knocked down with the UAS-Gal4 system 116 to induce conditional RNAi. The pan-neuronal promoter line w1118; 2xGMR-wIR; elav-Gal4, UAS-Dicer-2 (ref. 42 ) and two independent RNAi constructs per gene were used whenever available (VDRC) 117 , thereby fulfilling stringent specificity criteria (s19 value ≥0.98) 118 . Strains containing identical genetic backgrounds to the RNAi constructs (no. 60000 and no. 60100) were crossed to the driver line and used as controls. No effects in our assays were observed when crossing the '40DUAS' line 119 (containing UAS repeats but no functional short hairpin RNA, a potential source of dominant phenotypes due to an integration locus of the VDRC KK library 119, 120 ) to our pan-neuronal Gal4 driver. Flies were cultured according to standard procedures. Experimental randomization was not applicable to the Drosophila experiments, and power calculations were not performed in this study.
Drosophila light-off jump-reflex habituation assay. The Drosophila light-off jump habituation assay was performed as previously described 121 . Briefly, flies were reared at 25 °C and 70% humidity, in a 12-h:12-h light/dark cycle. For all healthy lines, at least 64 3-to 7-d-old male flies were tested per genotype, in at least two independent experiments. Flies were transferred into individual vials of two 16-unit habituation systems (Aktogen) and, after a 5-min adaptation, were exposed to 100 light-off pulses (15 ms each) with a 1-s interpulse interval. Jump responses were recorded by two sensitive microphones placed in each vial. A carefully chosen threshold was applied to distinguish the jump responses from the background noise. Data from 64 individual flies per genotype were collected (two independent experiments) and analyzed with custom Labview Software (National Instruments). Investigators were blinded to genotypes during the experiments, and data were automatically analyzed. Flies that jumped at least once in the first five trials were evaluated for habituation (preestablished criterion). Initial jumping responses to light-off pulse decreased with the number of pulses, and flies were considered to be habituated when they stopped jumping for five consecutive trials (no-jump criterion). Habituation was scored as the number of trials to the no-jump criterion (TTC). The main effect of genotype, corrected for testing day and 16-unit system on TTC values, was determined through linear-model regression analysis with R statistical software (v.3.0.0).
Drosophila neuromuscular junction (NMJ) experiments.
Flies were reared at 28 °C, 60% humidity and a 12-h:12-h light/dark cycle. Type 1b NMJs of muscle 4 were analyzed. Wandering third-instar larvae were collected, dissected and fixed in 3.7% paraformaldehyde for 30 min. Preparations were rinsed with PBS and permeabilized with 0.3% Triton X-100 in PBS for 2 h at room temperature. Discs large protein (Dlg1) was visualized with the primary antibody anti-Dlg1 (1:25) (Dlg1-4F3, Developmental Studies Hybridoma Bank) conjugated with the Zenon Alexa Fluor 568 Mouse IgG1 labeling kit (Invitrogen), according to the manufacturer's protocol. Antibody validation is provided on the vendors' websites. The preparations were incubated for 1.5 h at room temperature, extensively washed, and mounted in ProLong Gold Antifade Mountant (Thermo Fisher Scientific). Investigators were blinded to genotypes during the experiments, and data were automatically analyzed. On the basis of previous experience [38] [39] [40] , fluorescence images were acquired for each genotype with an automated Leica DMI6000B high-content microscope. Morphometric analysis was performed in FIJI 122 with the Drosophila NMJ Morphometrics macro 123 . The resulting images were visually inspected for accurate image segmentation. Inaccurately segmented parameters were excluded, as previously described 123 . The NMJ bouton number in Hmt4-20-knockdown flies was manually assessed by two independent investigators blinded to genotype, and data were averaged to obtain the final counts. Statistical analysis was performed with GraphPad PRISM. The area, perimeter, length, longest branch length, and number of boutons were analyzed with Student's t-tests. The number of branches, branching points, and islands were analyzed with Mann-Whitney U tests.
Statistical analyses.
To calculate the significance and penetrance of LGD and MIS30 mutations in ASD/ID, we compared our smMIP data against two control data sets: the first included the 2,867 unaffected-sibling controls that were sequenced through the same smMIP pipeline (described above), and the second included mutation data from the ExAC database 75 , in which neuropsychiatric cases were removed (ExAC v0.3), representing 45,376 samples. The .vcf file for these 45, 376 ExAC samples was annotated with VEP and CADD (as described above). The ExAC data set was filtered through the same pipeline as the smMIP data (described above) including only 'PASS' variants. Private variants were filtered as an AC = 1 for burden statistics. To compare the ExAC control counts and the smMIP data, only LGD and MIS30 events were considered. LGD and MIS30 counts by gene for ExAC can be found in Supplementary Table 18 . To calculate the significance of private LGD or MIS30 mutation burden in our smMIP data set compared with unaffected (ExAC) controls, we performed a simulation by shuffling the labels of private case and control observations 1 × 10 6 times and calculated the probability of observing at least the number of LGD or MIS30 events seen among our cases. These P values were corrected (Benjamini-Hochberg) for the number of genes in the study (n = 208). Penetrance and its confidence bounds were calculated with a previously described model 36 :
where D is disease, G is genotype (the presence of the specific type of event in the gene), and D is the absence of disease. The general population incidence of ID/DD in our cohort was assumed to match that described in Rosenfeld et al. 35, 36 (P(D) = 5.12%), because our cohort composition has a similar representation of youth-onset diseases with an important genetic component with broad exclusion of chromosomal disorders. De novo significance was calculated as previously described 9 , using a statistical framework that considers the length of the gene and divergence between chimpanzees and humans. To calculate de novo significance for MIS30 variants, we modified the model to separately enumerate prior probabilities for CADD <30 and CADD ≥30 missense sites with CADD v1.3. To compare clinical phenotypes, a Pearson's correlation coefficient and P value were used to compare overall ASD versus ID diagnosis on the basis of genic event. Phenotypic rates were compared among individuals carrying variants in ASD versus DD genes with two-tailed Fisher's exact tests.
A linear-model regression analysis was performed with 64 flies per genotype, collected in two independent experiments, for the habituation data calculations. For the NMJ experiments, the area, perimeter, length, longest branch length, and number of boutons were analyzed with two-tailed Student's t-tests (degrees of freedom for SRCAP (dom) experiments: area = 60, length = 65, boutons = 73, perimeter = 60; degrees of freedom for TCF4 (da) experiments: area = 63, length = 68, branches = 68, branching = 68). Branches, branching points, and islands were analyzed with Mann-Whitney U tests.
Data availability. The smMIP sequencing data for this study can be downloaded from the NIMH data repository National Database for Autism Research (NDAR) at http://dx.doi.org/10.15154/1340671 and are available to all qualified researchers after data-use certification. Approved researchers can obtain the SSC population data set described in this study (http://sfari.org/resources/ simons-simplex-collection/) by applying at https://base.sfari.org/.
